Trial Profile
Prospective Study of Plasma Biomarkers Associated with the Inflammatory Response in Type 1 Gaucher Disease Patients Treated During One Year with Velaglucerase Alfa
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2015
Price :
$35
*
At a glance
- Drugs Velaglucerase alfa (Primary)
- Indications Gaucher's disease type I
- Focus Biomarker; Pharmacodynamics
- 04 Aug 2015 New trial record
- 14 Jun 2015 Results presented at the 20th Congress of the European Haematology Association.